Boehringer Ingelheim
For Healthcare Professionals
Metalyse Ph_Banner_image-2x

Single IV bolus administration

Tenecteplase (Metalyse®) 25 mg is administered by a single IV bolus over 5 to 10 seconds, eliminating the need for a one-hour infusion, as required for Alteplase (Actilyse®)

BEMM||Administration

Tenecteplase (Metalyse®) 25 mg is quick and easy to use and does not require an 
infusion pump - simplifying preparation, saving time and cost, 
as well as reducing dosing errors*1-5

BEMM||Administration
Disclaimer: This photo is for demonstration purposes only. Actual label and commercial presentation may vary per country according to local registrations.

 

  • Tenecteplase (Metalyse®) 25 mg comes as one single vial of powder for reconstitution, regardless of patient weight

  • The dosing for Tenecteplase (Metalyse®) 25 mg is simple with only 5
weight-based tiers:

BEMM||Administration
BEMM||Administration
BEMM||Administration

PDF Document for Preparation and Administration 
PC-PH-XXXXXX June 2025
Learn more

Why is Tenecteplase (Metalyse®) 25 mg quicker and easier to use compared to Alteplase (Actilyse®)

Tenecteplase is a genetically modified version of alteplase. Mutations in the protein sequence increased the specificity of Tenecteplase Metalyse©  to fibrin and made it more resistant to natural inhibitors, which increased its half-life and allowed for shorter treatment duration.6-7

BEMM||Administration
BEMM||Administration

Footnotes

  • IV: intravenous; PAI-1: plasminogen activator inhibitor-1.
  • *
    One of the common contributing factors that led to dosing errors associated with alteplase administration was the infusion pump being programmed incorrectly. Additionally, a single IV bolus administration avoids the interruption of treatment, further reducing dosing errors.
  • †
    Tenecteplase was administrated within 4.5 hours after onset of stroke symptoms, as a weight-tiered bolus dose, based on 0.25 mg/kg by 10 kg steps, for the maximum weight at each tier: < 60 kg, 15 mg tenecteplase; ≥ 60 to < 70 kg, 17.5 mg; ≥ 70 to < 80 kg, 20 mg; ≥ 80 to < 90 kg, 22.5 mg; and ≥ 90 kg, 25 mg.
References
  • 1.
     Tenecteplase Metalyse© European Summary of Product Characteristics.
  • 2.
     Menon BK, et al. Lancet 2022;400:161-169.
  • 3.
     Bivard A, et al. Lancet Neurol. 2022;21:520-27.
  • 4.
     Actilyse® European Summary of Product Characteristics.
  • 5.
     Dancsecs KA, et al. Am J Emerg Med. 2021;47:90-94.
  • 6.
     Miller, SE and Warach, SJ. Neurotherapeutics 2023;20:664-678.
  • 7.
     Zhu A, et al. Res Pract Thromb Haemost. 2022;6:e12795.
  • 8.
     Huang X, et al. Stroke 2015;46(12):3543-6.
  • 9.
     Tanswell P, et al. Clin Pharmacokinet. 2002;41(15):1229-45.

PC-PH-106488